Exchange: NASDAQ·Updated 07:34 PM EDT
News
all
press releases
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Larimar Therapeutics, Inc. - LRMR
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Larimar Therapeutics, Inc. - LRMR INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Larimar Therapeutics, Inc. - LRMR PR Newswire NEW YORK, July 23, 2026 NEW YORK, July 23, 2026...
PR Newswire
More News
Larimar Therapeutics (LRMR) Submits Initial Module of BLA For Nomlabofusp Therapy
Larimar Therapeutics (LRMR) Submits Initial Module of BLA For Nomlabofusp Therapy...
Yahoo! Finance: News
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Larimar Therapeutics, Inc. - LRMR
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Larimar Therapeutics, Inc. - LRMR INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Larimar Therapeutics, Inc. - LRMR PR Newswire NEW YORK, July 9, 2026 NEW YORK, July 9, 2026...
PR Newswire
LRMR Stock Edges Up After Hours After Director Purchases Shares Worth About $167,000
The shares were acquired in multiple transactions at prices ranging from $3.33 to $3.35 per share.
Stocktwits
LRMR Shares Hold Steady As Wall Street Optimism Offsets Drug Safety Concerns
H.C. Wainwright initiated coverage of Larimar with a ‘Buy’ rating and a $10 price target on Thursday.
Stocktwits
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Larimar Therapeutics, Inc. - LRMR
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Larimar Therapeutics, Inc. - LRMR INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Larimar Therapeutics, Inc. - LRMR PR Newswire NEW YORK, July 1, 2026 NEW YORK, July 1, 2026...
PR Newswire
Larimar Stock Slides 15% Despite FDA Backing Rolling Submission For Rare Disease Drug
Larimar Therapeutics Inc (LRMR) submits first module of Biologics License Application for investigational treatment for Friedreich's ataxia, with FDA support and positive long-term data showing durable safety profile and clinical improvements compared to natural history data.read more...
Benzinga
Larimar's Rare Disease Push Just Hit A Key Inflection Point — What Investors Need To Know
Larimar submitted the module of a rolling biologics license application to the U.S. Food and Drug Administration for the accelerated approval of nomlabofusp for Friedreich’s ataxia.
Stocktwits
Larimar Therapeutics, Inc. $LRMR Shares Acquired by AIGH Capital Management LLC
AIGH Capital Management LLC lifted its stake in shares of Larimar Therapeutics, Inc. (NASDAQ:LRMR - Free Report) by 100.0% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 2,000,000 shares of the compa...
MarketBeat
Larimar Therapeutics, Inc. (NASDAQ:LRMR) Given Consensus Recommendation of "Buy" by Brokerages
Shares of Larimar Therapeutics, Inc. (NASDAQ:LRMR - Get Free Report) have been assigned a consensus recommendation of "Buy" from the ten ratings firms that are presently covering the company, MarketBeat Ratings reports. One research analyst has rated the stock with a sell recommendation, six have...
MarketBeat

Advertisement|Remove ads.